Compare BBU & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBU | VERA |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.2B |
| IPO Year | 2015 | 2021 |
| Metric | BBU | VERA |
|---|---|---|
| Price | $31.46 | $42.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $39.40 | ★ $81.30 |
| AVG Volume (30 Days) | 48.7K | ★ 1.2M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $472.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $18.76 |
| 52 Week High | $37.75 | $56.05 |
| Indicator | BBU | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 51.88 |
| Support Level | $29.90 | $40.87 |
| Resistance Level | $36.93 | $42.77 |
| Average True Range (ATR) | 1.38 | 2.34 |
| MACD | 0.23 | 0.40 |
| Stochastic Oscillator | 46.92 | 45.16 |
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.